Company Overview and News


Add MDXG
to your dashboard

Headline News

MiMedx CEO Pete Petit suing short sellers after negative reports - Business Insider

2017-11-10 businessinsider
A flamboyant CEO critics calls the "Trump of Georgia" is engaged in a legal war with the nation's short-sellers — traders who bet a stock price will fall — and searching for the analysts who wrote anonymous blog posts about his small pharmaceutical company, MiMedx Group. (7-1)

petite parker the barker – MiMedx Group Inc (NASDAQ:MDXG)

2017-10-31 petiteparkerthebarker
(7-2)

MiMedx Group's (MDXG) CEO Pete Petit on Q3 2017 Results - Earnings Call Transcript

2017-10-28 seekingalpha
Good day ladies and gentlemen, and welcome to the Q3 2017 MiMedx Group Inc's Earnings Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session and instructions will follow at that time. [Operator Instructions]. (29-1)

Citron Chimes In On MiMedx. Countdown To Formal Investigation. $3 Price Target

2017-10-25 seekingalpha
Citron would not enter into a “noisy” game unless we can add insight into the short thesis and create a better informed marketplace for mentioned stock. (7-0)

MiMedx Adds New Materials To Its Website Exposing Misinformation Disseminated Through Short Seller Attacks

2017-10-13 prnewswire
MARIETTA, Ga., Oct. 13, 2017 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human placental tissue allografts and patent-protected processes for multiple sectors of healthcare, announced today that it has posted additional materials on the Company's website that further expose the misinformation disseminated through short seller attacks. (7-0)

Multicenter Randomized Controlled VLU Clinical Study Published In The Demonstrates Significantly Higher Healing Rates Of MiMedx EpiFix

2017-10-11 devicespace
MARIETTA, Ga., Oct. 11, 2017 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human placental tissue allografts with patent-protected processes for multiple sectors of healthcare, announced today that the latest peer-reviewed clinical study of MiMedx dehydrated human amnion/chorion membrane ("dHACM") allografts has been published in the International WoundJournal. (7-0)

MiMedx Group (MDXG) Looks Good: Stock Adds 5.4% in Session

2017-10-11 zacks
MiMedx Group, Inc. (MDXG - Free Report) was a big mover last session, as the company saw its shares rise more than 5% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This reverses the recent trend for the company—as the stock is now down 13.9% in the past one-month time frame. (48-0)

Technical Reports on Medical Equipment Equities -- Nxstage Medical, MiMedx, Hologic, and Wright Medical

2017-10-11 prnewswire
If you want a Stock Review on NXTM, MDXG, HOLX, or WMGI then come over to http://dailystocktracker.com/register/ and sign up for your free customized report. In today's pre-market research, DailyStockTracker.com shifts focus on four equities to see how they have fared at the close of the last trading session: Nxstage Medical Inc. (NASDAQ: NXTM), MiMedx Group Inc. (NASDAQ: MDXG), Hologic Inc. (NASDAQ: HOLX), and Wright Medical Group N. (100-0)

MiMedx Adds New Materials To Its Website Exposing Misinformation Disseminated Through Short Seller Attacks

2017-10-10 devicespace
MARIETTA, Ga., Oct. 10, 2017 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human placental tissue allografts and patent-protected processes for multiple sectors of healthcare, announced today that it has posted additional materials on the Company's website that further expose the misinformation disseminated through short seller attacks. (7-0)

MiMedx Adds New Materials To Its Website Exposing Misinformation Disseminated Through Short Seller Attacks

2017-10-10 prnewswire
MARIETTA, Ga., Oct. 10, 2017 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human placental tissue allografts and patent-protected processes for multiple sectors of healthcare, announced today that it has posted additional materials on the Company's website that further expose the misinformation disseminated through short seller attacks. (7-0)

Final Surviving Claims In MiMedx Patent Infringement Lawsuit Against Scheduled To Go To Trial In January 2018

2017-10-10 devicespace
EDISON, N.J., Oct. 10, 2017 /PRNewswire/ -- Musculoskeletal Transplant Foundation (MTF) today announced that the patent infringement lawsuit brought by MiMedx Group, Inc., (MiMedx) against MTF, Liventa Bioscience, Inc., and Medline Industries, Inc., has been scheduled for trial on January 22, 2018. MTF is a nonprofit service organization and tissue bank with a mission to save and heal lives by honoring donated gifts, serving patients and advancing science. (7-0)

MiMedx Announces Third Quarter Revenues Of $84.6 Million Exceeds Guidance By More Than 5 Percent

2017-10-10 devicespace
MARIETTA, Ga., Oct. 10, 2017 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human placental tissue allografts and patent-protected processes for multiple sectors of healthcare, announced today its preliminary revenue results for the third quarter of 2017. (22-0)

MiMedx Board Of Directors Authorizes $10 Million Increase To The Company's Share Repurchase Program

2017-10-09 devicespace
MARIETTA, Ga., Oct. 9, 2017 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human placental tissue allografts and patent-protected processes for multiple sectors of healthcare, announced today the decision of its Board of Directors to authorize a $10 million increase in the Company's Share Repurchase Program. (22-0)

MiMedx Files Lawsuit Related To Short Seller Attacks

2017-10-04 devicespace
MARIETTA, Ga., Oct. 4, 2017 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human placental tissue allografts and patent-protected processes for multiple sectors of healthcare, announced today that the Company and one of its employees have filed a lawsuit against Viceroy Research and Sparrow Fund Research LP a/k/a Aurelius Value, John Fichthorn, BR Dialectic Capital Management, LLC, and "Does" 1-10, for libel, slander, defamation, false light, and tortious interference with business relations. (7-0)

CUSIP: 602496101